A database of FDA approved therapeutic peptides and proteins
ID1055 | ThPPIDTh1009 | NameAlteplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandActivase | CompanyGenentech Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous | CategoryThrombolytic Agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1067 | ThPPIDTh1012 | NameReteplase | Peptide SequenceSYQGNSDCYFGNGSAYRGTH Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandRetavase | CompanyCentocor | Physical AppearanceSterile, white, lyophilized powder | Route of AdministartionIntravenous Injection | CategoryFibrinolytic Agents, Thrombolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1117 | ThPPIDTh1016 | NamePegfilgrastim | Peptide SequenceMTPLGPASSLPQSFLLKCLE Full view | Length175 | Functional ClassificationIb | DiseaseImmunological | BrandNeulasta | CompanyAmgen Inc. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents, Anti-neutropenic agents | TargetGranulocyte colony-stimulating factor receptor,Neutrophil elastase |
ID1148 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAdvate | CompanyN.A. | Physical AppearancePowder form | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1149 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAlphanate | CompanyN.A. | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1150 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandBioclate | CompanyBaxter Healthcare Corporation, Hyland Division and Genetics Institute, Inc. | Physical AppearanceSterile, nonpyrogenic, off-white to faint yellow, lyophilized powder | Route of AdministartionIntravenous infusion | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1151 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandHelixate FS | CompanyN.A. | Physical AppearanceSterile, stable, purified, nonpyrogenic, dried concentrate | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1152 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandHemofil M | CompanyN.A. | Physical AppearanceDry concentrate | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1153 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandHyate:C | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1154 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandKoate-HP | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1155 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandKogenate FS | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1156 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandMonarc-M | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1157 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandMonoclate-P | CompanyN.A. | Physical AppearanceLyophilized powder for solution | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1158 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandReFacto | CompanyN.A. | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1159 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandXyntha | CompanyN.A. | Physical AppearanceSterile, nonpyrogenic, preservative-free, freeze-dried powder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1201 | ThPPIDTh1026 | NameAnistreplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIc | DiseaseHematological,Metabolic | BrandEminase | CompanyWulfing Pharma GmbH | Physical AppearanceDry powder | Route of AdministartionIntravenous infusion | CategoryThrombolytic Agents, Fibrinolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1205 | ThPPIDTh1027 | NameInsulin Regular | Peptide SequenceA-chain:GIVEQCCTSIC< Full view | Length51 | Functional ClassificationIa | DiseaseGenetic/Hormonal | BrandHumulin R | CompanyEli Lilly and Company | Physical AppearanceSterile, clear, aqueous, and colorless solution | Route of AdministartionSubcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm and Intravenousadministration of Humulin R (insulin (human recombinant)) U-100 is possible under medical supervision. | CategoryAntidiabetic Agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
ID1206 | ThPPIDTh1027 | NameInsulin Regular | Peptide SequenceA-chain:GIVEQCCTSIC< Full view | Length51 | Functional ClassificationIa | DiseaseGenetic/Hormonal | BrandNovolin R | CompanyNovo Nordisk | Physical AppearanceSterile, clear, aqueous, and colorless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAntidiabetic Agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
ID1210 | ThPPIDTh1028 | NameTenecteplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandTNKase | CompanyGenentech Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous Injection | CategoryThrombolytic Agents, Fibrinolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1,Plasminogen activator inhibitor 2,Tetranectin,Keratin, type II cytoskeletal 8,Annexin A2,Calreticulin,Calnexin,Prolow-density lipoprotein |
ID1234 | ThPPIDTh1032 | NameCoagulation factor VIIa | Peptide SequenceANAFLEELRPGSLERECKEE Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandNovoSeven | CompanyNovo Nordisk | Physical AppearanceSterile, white lyophilized powder | Route of AdministartionInjection | CategoryThrombotic Agents, Coagulants | TargetCoagulation factor X,Serine protease hepsin,Tissue factor pathway inhibitor,Vitamin K-dependent gamma-carboxylase,Coagulation factor VII,Tissue factor |
ID1246 | ThPPIDTh1034 | NamePalifermin | Peptide SequenceSYDYMEGGDIRVRRLFCRTQ Full view | Length140 | Functional ClassificationIb | DiseaseCancer | BrandKepivance | CompanyAmgen Inc | Physical AppearanceSterile, lyophilized powder | Route of AdministartionIntravenous infusion | CategoryAnti-Mucositis Agents | TargetFibroblast growth factor receptor 2,Neuropilin-1,Fibroblast growth factor receptor 1,Fibroblast growth factor receptor 4,Fibroblast growth factor receptor 3,Basement membrane-specific heparan sulfate proteoglycan core protein |
ID1331 | ThPPIDTh1047 | NameAlpha-1-proteinase inhibitor | Peptide SequenceEDPQGDAAQKTDTSHHDQDH Full view | Length255 | Functional ClassificationIIa | DiseaseMetabolic/Geneti/Respiratory | BrandAralast | CompanyBaxter | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous infusion | CategorySerine Proteinase Inhibitors, Enzyme replacement agents, trypsin inhibitors | TargetNeutrophil elastase |
ID1332 | ThPPIDTh1047 | NameAlpha-1-proteinase inhibitor | Peptide SequenceEDPQGDAAQKTDTSHHDQDH Full view | Length255 | Functional ClassificationIIa | DiseaseMetabolic/Geneti/Respiratory | BrandProlastin | CompanyTalecris Biotherapeutics C formerly Bayer | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous infusion | CategorySerine Proteinase Inhibitors, Enzyme replacement agents, trypsin inhibitors | TargetNeutrophil elastase |
ID1385 | ThPPIDTh1061 | NameTrastuzumab | Peptide SequenceLight chain 1: DIQMT Full view | Length1364 | Functional ClassificationIIa | DiseaseCancer | BrandHerceptin | CompanyGenentech | Physical AppearanceSterile, white to pale yellow, preservative-free lyophilized powder | Route of Administartion Intravenous administration | CategoryAntineoplastic Agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor,Insulin-degrading enzyme,HLA class II histocompatibility antigen, DQ alpha 2 chain,HLA class II histocompatibility antigen, DQ beta 1 chain,Retinoblastoma-associated protein,Cathepsin D,Carboxypeptidase E,Neuroendocrine convertase 2,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-related protein 2,Insulin-like growth factor-binding protein 7,Synaptotagmin-like protein 4 |
ID1389 | ThPPIDTh1062 | NameRituximab | Peptide SequenceHeavy Chain: QVQLQQP Full view | Length664 | Functional ClassificationIIa | DiseaseCancer/Immunological | BrandRituxan | CompanyBiogen Idec Inc., and Genentech USA, Inc | Physical AppearanceSterile, clear, colorless, preservative-free liquid concentrate | Route of Administartion Intravenous administration | CategoryAntineoplastic Agents, Immunologic Factors and Antirheumatic Agents | TargetB-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Receptor tyrosine-protein kinase erbB-2,Epidermal growth factor receptor,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor I |
ID1434 | ThPPIDTh1074 | NameAlglucerase | Peptide SequenceARPCIPKSFGYSSVVCVCNA Full view | Length497 | Functional ClassificationIa | DiseaseMetabolic | BrandCeredase | CompanyGenzyme Corporation | Physical AppearanceClear sterile non-pyrogenic solution of alglucerase in a citrate buffered solution | Route of AdministartionIntravenous injection | CategoryEnzyme Replacement Agents | TargetPlasminogen,Proteinase-activated receptor 1 |
ID1439 | ThPPIDTh1077 | NameUrofollitropin | Peptide SequenceAlpha chain:APDVQDCP Full view | Length203 | Functional ClassificationIb | DiseaseHormonal | BrandBRAVELLE | CompanyFerring Pharmaceuticals Inc. | Physical AppearanceSterile, lyophilized powder used after reconstitution with sterile 0.9% Sodium Chloride Injection | Route of AdministartionIntramuscular and Subcutaneous administration | CategoryFertility Agents | TargetGlutamate carboxypeptidase 2 |
ID1440 | ThPPIDTh1077 | NameUrofollitropin | Peptide SequenceAlpha chain:APDVQDCP Full view | Length203 | Functional ClassificationIb | DiseaseHormonal | BrandMetrodin | CompanyN.A. | Physical AppearanceSterile, lypholized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Route of AdministartionIntramuscular injection. | CategoryFertility Agents | TargetGlutamate carboxypeptidase 2 |
ID1441 | ThPPIDTh1077 | NameUrofollitropin | Peptide SequenceAlpha chain:APDVQDCP Full view | Length203 | Functional ClassificationIb | DiseaseHormonal | BrandFertinex | CompanyN.A. | Physical AppearanceSterile, lyophilized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Route of AdministartionSubcutaneous injection. | CategoryFertility Agents | TargetGlutamate carboxypeptidase 2 |
ID1456 | ThPPIDTh1086 | NameInterferon Alfa-2B, Recombinant | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandINTRON® A | CompanyMerck | Physical AppearancePowder or solution | Route of AdministartionIntramuscular, Subcutaneous, Intralesional, or Intravenous injection | CategoryImmunosuppressive Agents | TargetGranulocyte colony-stimulating factor receptor,Neutrophil elastase, Coagulation factor X,Coagulation factor XI,Coagulation factor VII,Coagulation factor VIII,Prothrombin,Prolow-density lipoprotein receptor-related protein 1,Vitamin K-dependent gamma-carboxylase, Platelet-derived growth factor receptor beta,Platelet-derived growth factor receptor alpha,Alpha-2-macroglobulin |
ID1560 | ThPPIDTh1121 | NamePertuzumab | Peptide Sequencelight chain DIQMTQSP Full view | Length664 | Functional ClassificationIIIc | DiseaseCancer | BrandPerjeta | CompanyGenentech | Physical AppearanceSterile, clear to slightly opalescent, colorless to pale brown liquid | Route of AdministartionIntravenous infusion | CategoryMonoclonal antibodies | TargetReceptor tyrosine-protein kinase erbB-2 |
ID1602 | ThPPIDTh1128 | NameVelaglucerase Alfa | Peptide SequenceARPCIPKSFGYSSVVCVCNA Full view | Length497 | Functional ClassificationIa | DiseaseHormonal | BrandVPRIV | CompanyShire | Physical AppearanceSterile, preservative free, lyophilized powder | Route of AdministartionIntravenous infusion | CategoryEnzymes | TargetGlucosylceramidase |
ID1659 | ThPPIDTh1152 | NameDrotrecogin alfa | Peptide SequenceHeavy Chain: LIDGKMT Full view | Length402 | Functional ClassificationIb | DiseaseInfectious | BrandXigris | CompanyEli Lilly and Company | Physical AppearanceSterile, lyophilized, white to off-white powder | Route of AdministartionIntravenous Infusion | CategoryAntisepsis | TargetCoagulation factor VIII, V, Plasminogen activator inhibitor 1, Thrombomodulin, Vitamin K-dependent protein S, Ceruloplasmin, Prothrombin, Platelet factor 4, Plasma serine protease inhibitor, Serpin B6, Vitamin K-dependent gamma-carboxylase, Endothelial protein C receptor |
ID1663 | ThPPIDTh1155 | NameUrokinase | Peptide SequenceKPSSPPEELKFQCGQKTLRP Full view | Length276 | Functional ClassificationIb | DiseaseHaemetological | BrandKinlytic | CompanyN.A. | Physical AppearanceSterile lyophilized white powder | Route of AdministartionIntravenous infusion | CategoryN.A. | TargetPlasminogen,Urokinase plasminogen activator surface receptor, Urokinase-type plasminogen activator, Tissue-type plasminogen activator, Plasminogen activator inhibitor 1, 2, Plasma serine protease inhibitor, Low-density lipoprotein receptor-related protein 2, Suppressor of tumorigenicity 14 protein, Nidogen-1 |
ID1678 | ThPPIDTh1162 | NameAlirocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIc | DiseaseMetabolic/Cardiac | BrandPraluent | CompanySanofi Aventis U.S. Llc | Physical AppearanceInjection, Solution | Route of AdministartionSubcutaneous | CategoryN.A. | TargetProprotein convertase subtilisin/kexin type 9 |
ID1679 | ThPPIDTh1162 | NameAlirocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIc | DiseaseMetabolic/Cardiac | BrandPraluent | CompanySanofi Aventis Canada Inc | Physical AppearanceSolution | Route of AdministartionSubcutaneous | CategoryN.A. | TargetProprotein convertase subtilisin/kexin type 10 |
ID1680 | ThPPIDTh1162 | NameAlirocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIc | DiseaseMetabolic/Cardiac | BrandPraluent | CompanySanofi Aventis Canada Inc | Physical AppearanceSolution | Route of AdministartionSubcutaneous | CategoryN.A. | TargetProprotein convertase subtilisin/kexin type 11 |
ID1681 | ThPPIDTh1162 | NameAlirocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIc | DiseaseMetabolic/Cardiac | BrandPraluent | CompanySanofi Aventis U.S. Llc | Physical AppearanceInjection, Solution | Route of AdministartionSubcutaneous | CategoryN.A. | TargetProprotein convertase subtilisin/kexin type 14 |
ID1715 | ThPPIDTh1171 | NameC1 Esterase Inhibitor (Human) | Peptide SequenceNA Full view | Length0 | Functional ClassificationIa | DiseaseGenetic Disorders | BrandBerinert 1500 | CompanyCsl Behring Canada Inc | Physical Appearancekit; Powder for Solution | Route of AdministartionIntravenous | CategoryNA | TargetPlasma protease C1 inhibitor |
ID1717 | ThPPIDTh1171 | NameC1 Esterase Inhibitor (Human) | Peptide SequenceNA Full view | Length0 | Functional ClassificationIa | DiseaseGenetic Disorders | BrandCinryze | CompanyViropharma Biologics Inc | Physical AppearancePowder for Solution | Route of AdministartionIntravenous | CategoryNA | TargetPlasma protease C1 inhibitor |
ID1724 | ThPPIDTh1174 | NameDaratumumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIc | DiseaseCancer | BrandDarzalex | CompanyJanssen Biotech, Inc. | Physical AppearanceSolution, concentrate | Route of AdministartionIntravenous | CategoryAntineoplastic Agents | TargetADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 |
ID1736 | ThPPIDTh1177 | NameElosulfase alfa | Peptide SequenceAPQPPNILLLLMDDMGWGDL Full view | Length496 | Functional ClassificationIa | DiseaseMetabolic Disorders | BrandVimizim | CompanyBiomarin International Limited | Physical AppearanceSolution | Route of AdministartionIntravenous | CategoryEnzymes; Alimentary Tract and Metabolism | TargetN-acetylgalactosamine-6-sulfatase |
ID1741 | ThPPIDTh1179 | NameEvolocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIa | DiseaseGenetic/Metabolic/Cardiac | BrandNA | CompanyNA | Physical AppearanceInjection, Solution; Injection | Route of AdministartionSubcutaneous | CategoryLipid Modifying Agents, Plain; Cardiovascular System | TargetProprotein convertase subtilisin/kexin type 9 |
ID1742 | ThPPIDTh1179 | NameEvolocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIa | DiseaseGenetic/Metabolic/Cardiac | BrandRepatha | CompanyAmgen Inc | Physical AppearanceInjection, Solution | Route of AdministartionSubcutaneous | CategoryLipid Modifying Agents, Plain; Cardiovascular System | TargetProprotein convertase subtilisin/kexin type 10 |
ID1743 | ThPPIDTh1179 | NameEvolocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIa | DiseaseGenetic/Metabolic/Cardiac | BrandRepatha | CompanyAmgen Canada Inc | Physical AppearanceSolution | Route of AdministartionSubcutaneous | CategoryLipid Modifying Agents, Plain; Cardiovascular System | TargetProprotein convertase subtilisin/kexin type 11 |
ID1744 | ThPPIDTh1179 | NameEvolocumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIa | DiseaseGenetic/Metabolic/Cardiac | BrandRepatha | CompanyAmgen Inc | Physical AppearanceInjection, Solution | Route of AdministartionSubcutaneous | CategoryLipid Modifying Agents, Plain; Cardiovascular System | TargetProprotein convertase subtilisin/kexin type 12 |
ID1821 | ThPPIDTh1212 | NameInsulin Pork | Peptide SequenceA chain GIVEQCCTSICS Full view | Length68 | Functional ClassificationIa | DiseaseMetabolic Disorders | BrandIletin II | CompanyLilly | Physical Appearancesterile suspension | Route of AdministartionSubcutaneous | CategoryHypoglycemic Agents, Antidiabetic Agents | TargetInsulin receptor, Insulin-like growth factor 1 receptor, Insulin-degrading enzyme, HLA class II histocompatibility antigen, DQ alpha 2 chain, HLA class II histocompatibility antigen, DQ beta 1 chain, Retinoblastoma-associated protein, Cathepsin D, Carboxypeptidase E, Neuroendocrine convertase 2, Neuroendocrine convertase 1, Protein NOV homolog, Low-density lipoprotein receptor-related protein 2, Insulin-like growth factor-binding protein 7, Synaptotagmin-like protein 4, Cytochrome P450 1A2 |
ID1848 | ThPPIDTh1236 | NameSipuleucel-T | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIc | DiseaseCancer | BrandProvenge | CompanyNA | Physical AppearanceSolution | Route of AdministartionIntravenous | CategoryAntineoplastic and Immunomodulating Agents | TargetProstatic acid phosphatase |